May 8, 2020 / 12:32 PM / 23 days ago

BRIEF-Ocugen Provides Business Update and First Quarter 2020 Financial Results

May 8 (Reuters) - Ocugen Inc:

* Q1 LOSS PER SHARE $0.07

* REMAIN ON TRACK TO ADVANCE FIRST GENE THERAPY PRODUCT CANDIDATE, OCU400, INTO CLINIC IN 2021

* EXPECT TOPLINE RESULTS BY END OF YEAR IN PHASE 3 TRIAL WITH OCU300 FOR OCULAR GRAFT VERSUS. HOST DISEASE Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below